Healthcare & Life Sciences

Acupuncture Medication Anxiety Depression Kunshan China

A Phase 4 clinical trial is registered on ClinicalTrials.gov (NCT07552246) studying acupuncture as a treatment for anxiety and depression. The trial is conducted in Kunshan, China. This is an informational registration entry only — no substantive study details, enrollment numbers, or compliance obligations are provided in the available content.

CSF Shunt Infection Hydrocephalus Children Egypt NCT07547826

ClinicalTrials.gov has registered a new Phase 4 interventional study (NCT07547826) titled 'CSF Shunt Infection Hydrocephalus Children Egypt'. The trial investigates cerebrospinal fluid shunt infection in pediatric patients with hydrocephalus. Egypt is listed as the overall location for the study. Phase 4 trials are post-marketing studies conducted after regulatory approval.

Antibiotic Prophylaxis in Surgery Trial in Somerset, New Jersey

A Phase 4 clinical trial registered on ClinicalTrials.gov investigating antibiotic prophylaxis during surgical procedures. The trial is conducted in Somerset, New Jersey. This is an informational registry entry providing basic trial details including location, intervention type, and phase classification.

Recurrent Erysipelas Trial Across 25 Locations in France

A Phase 4 clinical trial (NCT07549594) investigating interventions for recurrent erysipelas has been registered on ClinicalTrials.gov. The trial is conducted across 25 locations in France, indicating a multi-center study design. ClinicalTrials.gov is maintained by the National Library of Medicine, part of the National Institutes of Health, and serves as a public registry for clinical studies.

Acute Severe Ulcerative Colitis, Four Locations, Shaanxi, China

A Phase 4 clinical trial investigating acute severe ulcerative colitis has been registered on ClinicalTrials.gov with identifier NCT07550673. The trial is conducted at four locations in Shaanxi, China. ClinicalTrials.gov is the primary registry for clinical research in the United States, maintained by the National Library of Medicine at the NIH.

Phase 4 Myofascial Pain Trial Kyrenia Cyprus

A Phase 4 clinical trial evaluating myofascial pain treatment is registered in ClinicalTrials.gov under NCT07547605. The trial is located in Kyrenia, Cyprus. Phase 4 trials assess treatment safety and effectiveness in larger patient populations following initial regulatory approval.

Phase 4 Trial, Dexmedetomidine, Myocardial Injury, Hangzhou

A Phase 4 clinical trial registered on ClinicalTrials.gov (NCT07549282) is studying dexmedetomidine for myocardial injury in surgical patients. The single-center trial is conducted in Hangzhou, China. This registry entry documents the trial's existence and basic parameters as part of the ClinicalTrials.gov Phase 4 trial database.

Phase 3 CBD Trial, Jiu-Jitsu Athletes, Pain, Sleep

A Phase 3 clinical trial (NCT07552974) registered by the NIH on ClinicalTrials.gov is investigating the effects of CBD on pain and sleep outcomes in Jiu-Jitsu athletes. The trial was started on September 1, 2022, and is classified as an interventional study examining a botanical CBD intervention for athletic performance and recovery. This registration provides public transparency on the trial's scope and participant population of 52 participants.

MagMen-II Phase 3 Sentinel Node Melanoma Trial

NIH has registered the MagMen-II clinical trial (NCT07552597) on ClinicalTrials.gov as a Phase 3 study evaluating sentinel node biopsy procedures in melanoma patients. The trial is listed in the registry with standard enrollment information. Clinical trial registrations on ClinicalTrials.gov are informational entries that do not create compliance obligations for third parties.

Phase 3 Rectal Cancer Trial, Microsatellite Stable

NIH's ClinicalTrials.gov registry has registered a Phase 3 clinical trial (NCT07551479) evaluating treatment for microsatellite stable rectal cancer. The trial is indexed under Phase 3 status with a start date tracked in the registry. This entry provides standardized trial information including eligibility criteria, study design, and contact details for prospective participants and investigators.

Filgotinib Phase 3 JIA Extension Trial, France Germany UK

A Phase 3 extension trial for filgotinib in juvenile idiopathic arthritis (JIA) has been registered on ClinicalTrials.gov. The trial is being conducted across France, Germany, and the United Kingdom. Filgotinib is an investigational drug being evaluated for extended treatment in JIA patients who previously completed a qualifying parent study.

Phase 3 Hypertension Diabetes Trial, Seoul

A Phase 3 clinical trial evaluating treatments for hypertension and diabetes has been registered on ClinicalTrials.gov under identifier NCT07552389. The trial is being conducted in Seoul, South Korea. ClinicalTrials.gov is maintained by the National Institutes of Health (NIH) National Library of Medicine as a publicly accessible registry of clinical studies.

ANKTIVA IL-15 BCG Phase 3 Bladder Cancer Study

This ClinicalTrials.gov registry entry documents a Phase 3 clinical trial evaluating ANKTIVA (IL-15) in combination with BCG (Bacillus Calmette-Guerin) for the treatment of bladder cancer. The registry record is maintained by the National Institutes of Health (NIH) as part of its clinical trial transparency initiative. No enrollment numbers, start dates, or location information are provided in this source summary.

Periodontal Disease Treatment, Low Birth Weight, Rural Nepal (Phase 3)

A Phase 3 clinical trial (NCT07553286) has been registered on ClinicalTrials.gov studying periodontal disease treatment as an intervention to reduce low birth weight in rural Nepal. The trial is listed as the top result when filtering Phase 3 trials by start date. This registry entry documents a planned interventional study targeting maternal oral health as a potential factor in infant birth weight outcomes.

Phase 3 IVIG Trial for Stiff Person Syndrome Adults

A Phase 3 clinical trial evaluating intravenous immunoglobulin (IVIG) as a treatment for Stiff Person Syndrome in adult patients is registered on ClinicalTrials.gov under the identifier NCT07552987. The trial is listed by start date in the registry and presents summary registration details including intervention type, study phase, and condition. No new compliance obligations or regulatory actions are imposed by this registry entry.

Natco Thalidomide ANDA 213267 Approved April 24

The FDA granted approval to NATCO for Abbreviated New Drug Application (ANDA) 213267, covering Thalidomide capsules in 50mg, 100mg, and 200mg strengths, all designated Prescription status with TE Code AB. A prior approval action on 04/27/2023 (ORIG-1) covered the same 50mg strength. The 150mg strength is listed as Discontinued. NATCO's product is not designated as the Reference Listed Drug (RLD), which remains Bristol-Myers Squibb's THALOMID.

Saphnelo (anifrolumab-fnia) BLA 761451 Approved April 24 2026

AstraZeneca AB received FDA approval on April 24, 2026 for Saphnelo (anifrolumab-fnia), a biologic drug product, under BLA 761451. The approved formulations include a 300MG/2ML (150MG/ML) single-use vial and a 120MG/0.8ML injection, both for prescription use only. The approval letter and supporting documentation are available through the FDA Drugs@FDA portal.

Alembic Generic Fingolimod Hydrochloride 0.5mg Capsule Approved

The FDA approved Alembic Pharmaceuticals' Abbreviated New Drug Application (ANDA 207974) for Fingolimod Hydrochloride 0.5mg oral capsules on April 24, 2026. The generic drug carries a therapeutic equivalence (TE) code of AB, indicating it is bioequivalent to the reference listed drug Gilenya by Novartis. Fingolimod is used to treat patients with relapsing forms of multiple sclerosis.

Clinical Laboratory Fee Schedule: Reporting Private Payor Data Booklet

CMS Medicare Learning Network published a booklet (MLN7358441) explaining how Medicare uses private payor data to set clinical laboratory test payment rates and what reporting obligations apply to clinical laboratories under the Clinical Laboratory Fee Schedule. The publication serves as an educational resource for laboratories navigating Medicare payment policy.

OHCA Issues $2,000 Administrative Penalty Against Reymando Fiesta

The Hawaii Department of Health Office of Health Care Assurance (OHCA) has issued a final order against Reymando Fiesta, operator of a Community Care Foster Family Home, following enforcement action for four separate and unrelated incidents where Fiesta left clients unattended or without a certified caregiver in violation of Hawaii Administrative Rules Chapter 11-800. Fiesta has been assessed a $2,000 administrative penalty and his CCFFH certificate has been revoked. Fiesta has 20 days from receipt of the order to submit a written request for a hearing; if no request is made, the order will become final and enforceable after that period.

First Clade I Mpox Detected at O'ahu Wastewater Sampling Site on Joint Base Pearl Harbor Hickam

The Hawai'i Department of Health detected clade I mpox in a wastewater sample collected on April 13, 2026, from Joint Base Pearl Harbor Hickam (JBPHH), the first-ever clade I detection in Hawaiian wastewater. Confirmatory positive results were received on April 24, 2026. No clinical cases of clade I mpox have been identified in Hawaii, and DOH states the risk for the general public is low. A subsequent sample collected April 20 from the same facility tested negative. DOH is encouraging vaccination with two doses of JYNNEOS for individuals at higher risk of mpox infection, available at the STI/HIV Clinic at Diamond Head Health Center and retail pharmacies.

MultiSense Patch Reduces Hospital Stay After GI Surgery

The SENSE-ECO study is a prospective, randomized trial of 490 high-risk patients designed to show that the MultiSense® remote monitoring patch safely reduces hospital stays following major digestive surgery. By continuously tracking vital signs for five days at home, the device aims to maintain clinical safety and quality of life while decreasing overall healthcare costs for the French medical system. The study registration NCT07552805 was posted on April 27, 2026.

NCT07552480: Goserelin for Ovarian Preservation in Allo-HSCT Patients

This is a prospective, multicenter, randomized controlled clinical trial registered on ClinicalTrials.gov under identifier NCT07552480, evaluating goserelin for preservation of ovarian function in 64 female patients aged 14-50 with malignant hematologic diseases undergoing allogeneic hematopoietic stem cell transplantation. The study enrolled 64 patients divided by conditioning type (MAC vs. non-MAC), then randomized 1:1 within each group to receive a single 3.6 mg subcutaneous goserelin injection 1-3 days prior to conditioning or no goserelin. The primary endpoint is menstrual recovery rate at 6 months post-transplantation, with secondary endpoints including incidence of premature ovarian insufficiency, ovarian reserve markers (AMH, FSH, LH, E2), ovarian volume, and endometrial thickness.

Observational Study Uses AI for Dental, Orthodontic Imaging Analysis

This registry entry documents NCT07551622, an observational study evaluating deep learning-based AI models for craniomaxillofacial multi-modal imaging analysis in dentistry, orthodontics, and oral maxillofacial practice. The study plans to enroll approximately 2,000 participants, analyzing 2D facial photographs, cone-beam CT images, and 3D facial surface scans to support image classification, anatomical landmark detection, segmentation, abnormality recognition, and treatment-related decision-making. The AI models are explicitly designed as clinical decision-support tools and are not intended to replace professional diagnosis or individualized treatment planning.

Mobile App Versus Tell-Show-Do Technique for Pediatric Dental Anxiety in Karachi: Multicenter Randomized Controlled Trial

This registration documents a multicenter randomized controlled trial comparing a mobile application-based behavioral intervention versus the conventional tell-show-do (TSD) technique for managing dental anxiety in children aged 7-11 years attending their first dental visit at tertiary care dental hospitals in Karachi, Pakistan. Participants are randomly assigned to either intervention prior to a dental diagnostic procedure. The primary outcomes are changes in pulse rate and anxiety levels measured using the Raghavendra Madhuri Sujata Pictorial Scale (RMS-PS) before and after the intervention.

Disease Activity Monitoring in Patients With Giant Cell Arteritis Study

An observational clinical study (NCT07552636) registered on ClinicalTrials.gov evaluating tools for monitoring disease activity and predicting relapses in patients with Giant Cell Arteritis (GCA). The study will enroll up to 175 patients with GCA in remission, with a target of 144 participants completing 1 year of follow-up. Participants will undergo vascular ultrasonography with double-blinded relapse assessment, complete patient-reported outcome measures, and provide biobank blood samples.

Phase 3 NCT07552389 Trial: HL1113R1/R2 vs HL1113 in Hypertension and Diabetes

Phase 3 clinical trial NCT07552389 registered April 27, 2026, evaluating HL1113R1/R2 monotherapy versus HL1113 fixed-dose combination in patients with essential hypertension and type II diabetes mellitus. The multi-center, randomized, double-blind study will assess efficacy and safety across four intervention groups (test, exploratory test, and two control groups). Pharmaceutical manufacturers, clinical research organizations, and healthcare institutions involved in diabetes and cardiovascular research should monitor this trial for competitive intelligence and patient recruitment updates.

Phase 4 Acupuncture vs Medication for Anxiety and Depression in China

A new Phase 4 clinical trial (NCT07552246) has been registered comparing acupuncture against standard SSRI medication for treating anxiety and mild-to-moderate depression in adults in China. The study aims to identify the most cost-effective and environmentally sustainable intervention between the two approaches. Conditions studied include Anxiety and Depression, with interventions including Selective Serotonin Reuptake Inhibitor (SSRI) and Acupuncture as standalone comparators.

Michigan DHHS Launches Gun Lock Map, 150 Sites for Free Firearm Safety

The Michigan Department of Health and Human Services launched a new statewide Gun Lock Distribution Map identifying 150 locations where Michigan residents can obtain free cable-style gun locks. The free locks are provided by Michigan State Police through Project ChildSafe, a nationwide firearm safety initiative. Community organizations, health departments, local governments, and other partners can request to become distribution sites by completing an online survey and will receive locks shipped directly upon approval. MDHHS stated that safe firearm storage helps prevent unintentional shootings, youth access to firearms, and suicide.

Hepatitis Gains Made, 2030 Targets Need Acceleration

The 2026 Global Hepatitis Report documents measurable progress since 2015: hepatitis B new infections dropped 32% globally, hepatitis C deaths fell 12%, and 85 countries have achieved or surpassed the 2030 target of 0.1% hepatitis B prevalence in children under five. However, 287 million people were living with chronic hepatitis B or C in 2024, with only 5% of hepatitis B patients receiving treatment and just 20% of hepatitis C patients treated since 2015. The WHO Director-General noted that while elimination is achievable with sustained political commitment, urgent scale-up of prevention, diagnosis, and treatment is needed to meet 2030 targets.

WHO Convenes 26 Countries for Exercise Polaris II Simulated Disease Outbreak Response

WHO concluded Exercise Polaris II, a 2-day high-level simulation exercise on April 22–23, 2026, based on a fictional new bacterium spreading globally. The exercise engaged 26 countries and territories, 600 health emergency experts, and over 25 partners including Africa CDC, UNICEF, MSF, and the Global Outbreak Alert and Response Network. Participants activated emergency coordination structures, tested information-sharing protocols, and practiced workforce surging under real-life conditions, operationalizing two key WHO frameworks: the Global Health Emergency Corps (GHEC) framework (June 2025) and the National health emergency alert and response framework (October 2025).

Swedish MPA Positive on EU Biotech Proposal, Warns on Patient Safety

Läkemedelsverket (Swedish Medical Products Agency) has submitted its response to an EU consultation on proposed biotech regulation. The agency expresses conditional support for the EU proposal but warns that additional strengthening is needed to adequately protect patient safety. This positions Sweden among EU member states providing input on the draft regulation.

Läkemedelsverket på Vitalis 2026, Göteborg, 5-7 maj

Läkemedelsverket (Swedish Medical Products Agency) announces its participation in Vitalis 2026, an annual healthcare digitalization conference held at Svenska Mässan in Gothenburg, Sweden, May 5-7, 2026. The agency will host sessions covering drug logistics, clinical trials, responsible AI use in healthcare, European Health Data Space (EHDS), drug shortage prevention, and supervision of national medical information systems. The agency shares booth B07:17 with Socialstyrelsen, E-hälsomyndigheten, SKR, and Inera.

Semaglutid 476 Och Tirzepatid 382 Rapporter 2025

Läkemedelsverket (Swedish Medicines Agency) published 2025 adverse drug reaction statistics showing 12,615 total spontaneous reports received, stable from the prior year. Healthcare providers submitted 7,382 reports while private individuals submitted 5,233. Semaglutide (476 reports) and tirzepatide (382 reports) topped the list of most-reported substances, used for type 2 diabetes and weight control. The agency emphasized that most reports are classified as non-serious and involve known side effects, while noting increased prescribing as a contributing factor.

Phase 1 Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

A prospective, open-label, exploratory Phase 1 clinical study (NCT07551778) evaluating the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy across three cohorts: advanced non-squamous NSCLC, advanced colorectal adenocarcinoma, and a lymphodepletion exploration cohort. The trial enrolled patients with locally advanced or metastatic solid tumors as of April 27, 2026. This registry entry documents the study design and does not impose compliance obligations on any party.

Patient Reported Outcome Measurements Registration in Spinal Pathologies and Neuromodulation

A prospective observational clinical registry has been registered on ClinicalTrials.gov under identifier NCT07552519. The study will collect longitudinal data through questionnaires and categorical diagnostic and therapeutic registration for patients with spinal pathologies and neuromodulation. Conditions include Spinal Pathologies, Pain, Cervical Pain, Lumbar Pain Syndrome, Neurostimulation, and Disc Degenerative Disease. This registration is for informational purposes and does not impose any compliance obligations.

Effect of TMJ Arthrocentesis on Capsular Width: An Ultrasonographic Study

ClinicalTrials.gov registration for NCT07553078, a prospective cohort study at Van Yuzuncu Yil University, Turkey, evaluating the effect of temporomandibular joint arthrocentesis on articular capsular width using ultrasonography. The study received ethics approval (2025/02-07) from Van Yuzuncu Yil University Clinical Research Ethics Committee on February 28, 2025, and is registered as of April 27, 2026. Participants with unilateral intra-articular TMJ disorder receive arthrocentesis with sterile Ringer's lactate solution using a two-needle technique.

Injectable Bioactive Giomer Composite vs Hall Technique for Proximal Cavities in Primary Molars

A randomized clinical trial has been registered on ClinicalTrials.gov (NCT07552129) comparing the survival rate and clinical performance of injectable bioactive giomer composite restorations versus the Hall Technique for managing proximal carious lesions (ICDAS 3-4) in primary molars of children aged 3-8 years over a 12-month follow-up period. The study lists dental caries as the condition and giomer and Hall technique as the interventions under study. This registry entry documents the trial protocol and recruitment parameters for interested clinical investigators and institutional review boards.

Art-Based Intervention for Hematological Cancer Patients: Randomized Controlled Trial

A randomized controlled experimental study registered on ClinicalTrials.gov (NCT07551817) examining the effect of art-based intervention on fatigue, anxiety, perception of nurse presence, and quality of life in patients with hematological cancer. The study will enroll 52 patients split into intervention and control groups (26 each) at a training and research hospital Hematology department from May 2025 to October 2026. The intervention group receives art-based sessions three times per week for two weeks, while the control group receives no intervention. Data collection uses Patient Identifier Information Form, Cancer Fatigue Scale, FACT-G, HADS, and Nurse Presence Scale.

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients

A behavioral intervention study registered on ClinicalTrials.gov (NCT07552571) will investigate how goal commitment theory, prospect theory, and evolutionary game theory explain the gap between knowledge and action in chronic disease patients. The parallel controlled trial will enroll patients with hypertension, diabetes mellitus, and dyslipidemia and compare a Stimulus-Organism-Response (SOR) model-based goal commitment intervention against usual care. No regulatory obligations or compliance requirements are imposed by this registry entry.

Random Controlled Trial of Home-Based Digital Therapy for ADHD in Children

NIH registered a new randomized controlled trial (NCT07552909) on ClinicalTrials.gov to evaluate the efficacy of home-based digital neurofeedback games as an intervention for school-aged children diagnosed with mild to moderate ADHD. The study will explore the effects of brain-controlled games on core ADHD symptoms. This registry entry establishes the formal study record and intervention protocol. No compliance obligations or enforcement actions are associated with this registration.

Daily Screen Time and Postoperative Delirium in Children Study

A prospective observational study (NCT07552896) registered with ClinicalTrials.gov on April 27, 2026, will examine the association between daily screen exposure duration and postoperative emergence delirium in 60 children aged 2 to 11 years undergoing elective lower abdominal surgery. The study will assess daily screen time via parent-reported questionnaire preoperatively and evaluate emergence delirium using the Pediatric Anesthesia Emergence Delirium scale at 5, 10, 15, and 30 minutes post-surgery.

Honey Bee Venom Immunotherapy Randomised Safety Study, Victoria

The Royal Melbourne Hospital has registered a Phase 0 randomised controlled pilot study comparing two honey bee venom immunotherapy (HBV-VIT) initiation strategies in adults sensitised to honey bee venom. The trial will enrol 24 participants at The Royal Women's Hospital (Parkville) and Monash Medical Centre (Clayton), Victoria, with anticipated first enrolment on 30 April 2026 and final data collection by 30 July 2027. Participants will be randomised to either direct 100-µg maintenance-dose initiation (weeks 0, 4, 8, 12) or ultrarush up-dosing (escalating doses over six weeks), with safety monitoring for systemic and local reactions across the 12-week induction period. The study aims to quantify immunologic changes (HBV-specific sIgE/sIgG4), blood tryptase, late-phase symptoms, and quality-of-life outcomes.

Osteopathy Versus Physiotherapy for Chronic Low Back Pain, Warsaw Poland

ANZCTR registration ACTRN12626000521325 for a completed comparative effectiveness trial conducted entirely in Warsaw, Poland, comparing osteopathic manual therapy versus conventional physiotherapy for non-specific chronic lumbosacral pain. The trial enrolled 84 participants (target 102), was approved by the Bioethics Committee of the Medical University of Warsaw on 15/04/2014, and was retrospectively registered on 28/04/2026 after data collection concluded on 25/02/2022. No individual participant data will be shared as the survey was conducted anonymously.

Deadly Fit Mums Exercise Program for Indigenous Mothers

The Deadly Fit Mums (DFM) program is an Aboriginal community-led exercise and nutrition education program registered as a clinical trial on ANZCTR (ACTRN12626000522314). The program serves pregnant and post-partum women birthing an Aboriginal and Torres Strait Islander baby through the Birthing in Our Community (BiOC) service across four sites in South East Queensland. The primary sponsor is Federica Barzi at the University of Queensland, with the Institute for Urban Indigenous Health as a collaborator and funding from the Australian Government Department of Health Medical Research Future Fund. Ethics approval was granted by The University of Queensland Human Research Ethics Committee (2025/HE000966) on 18/06/2025. The trial is registered retrospectively with enrollment of 1,300 participants completed between January 2023 and June 2025, and final data collection anticipated by June 2026.

Effect of Spinal and General Anesthesia on Frontal QRS Axis in Total Knee Arthroplasty

NIH registered study NCT07551648, a prospective observational trial comparing frontal QRS axis changes in patients undergoing total knee arthroplasty under spinal versus general anesthesia. The study will enroll adults aged 18 years and older with ASA physical status I to III, using standard 12-lead electrocardiography to measure preoperative-to-postoperative QRS axis changes. Enrollment criteria, methodology, and outcome measures are now publicly available on ClinicalTrials.gov for research transparency purposes.

Pilot Validation of STELA Digital Preventive Medicine Platform for Cardiovascular Risk Reduction in Adults

A pilot validation study for the STELA digital preventive medicine platform has been registered on ClinicalTrials.gov (NCT07551960) by researchers at AGEL Hospital Trinec-Podlesi in Czechia. The platform is designed to identify, quantify, and reduce modifiable cardiovascular health risk factors in adults without established cardiovascular disease through comprehensive health assessments, personalized prevention plans, and coordinated wellness interventions. The study uses the AGEL Gamification Index scoring system and involves participants undergoing extensive baseline assessments including laboratory panels, physical tests, and imaging studies.